Caricamento...
FLT3 inhibitors in acute myeloid leukemia
FLT3 mutations are one of the most common findings in acute myeloid leukemia (AML). FLT3 inhibitors have been in active clinical development. Midostaurin as the first-in-class FLT3 inhibitor has been approved for treatment of patients with FLT3-mutated AML. In this review, we summarized the preclini...
Salvato in:
| Pubblicato in: | J Hematol Oncol |
|---|---|
| Autori principali: | , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
BioMed Central
2018
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6280371/ https://ncbi.nlm.nih.gov/pubmed/30514344 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-018-0675-4 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|